Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology Ltd has applied to the ASX for quotation of 23,047 new fully paid ordinary shares, following the exercise or conversion of options or other convertible securities. The relatively small issuance modestly increases the company’s share capital and reflects ongoing conversion of existing equity instruments, with limited immediate impact on ownership structure but signalling continued engagement from holders of its options or convertible securities.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd (ASX: RAC) is an Australia-listed biotechnology company focused on oncology, developing and commercialising cancer therapies within the pharmaceutical and life sciences sector.
Average Trading Volume: 227,232
Technical Sentiment Signal: Buy
Current Market Cap: A$401.1M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.